Welcome to SureStone Capital, formerly Ausbiz CapitalSame team, same ABN and AFS authorisations. Our name changed on 1 October 2026.
All CSL Limited (ASX:CSL) announcement summaries, newest first. Every summary is drawn only from the company's official ASX release.
CSL reported a US$2.6bn FY26 net loss attributable to shareholders after US$7.1bn of pre-tax impairments, with underlying NPATA attributable of US$3.1bn.
18 Aug, 2026
CSL will trial immunoglobulin made with its yield-enhancing Horizon 2 process, with clinical activities to begin in mid-2027 after FDA and EMA engagement.
29 Jul, 2026
